In a report released today, Ritu Baral from TD Cowen maintained a Buy rating on Sarepta Therapeutics (SRPT – Research Report), with a price ...

TD Cowen analyst Ritu Baral maintained a Buy rating on Inventiva (IVA – Research Report) today. The company’s shares closed yesterday at ...

Jefferies equity analyst Andrew Tsai and Ritu Baral, a managing director and senior biotech analyst with TD Cowen, both observed. Elevidys is indicated for individuals at least four years old to ...

Alnylam Pharmaceuticals Inc. won expanded US approval for a heart drug that could be the biggest boon yet for the 23-year-old biotech — if it can beat out stiff competition from the likes of Pfizer ...

“We believe the urgent heart failure language could give Alnylam an advantage,” Ritu Baral, an analyst at TD Cowen, said, “especially for front-line use.” ...

TD Cowen analyst Ritu Baral provided insights from a key opinion leader (KOL) in orphan neuromuscular diseases, who spoke at an investor event hosted by the Muscular Dystrophy Association (MDA).

Gene therapy developer Sarepta Therapeutics (NASDAQ:SRPT) lost ~20% on Tuesday to reach a new 52-week low after the company disclosed the death of a patient treated with Elevidys, its FDA-approved ...

Gene therapy developer Sarepta Therapeutics (NASDAQ:SRPT) lost ~20% on Tuesday to reach a new 52-week low after the company disclosed the death of a patient treated with Elevidys, its FDA-approved ...

TD Cowen analyst Ritu Baral provided insights from a key opinion leader (KOL) in orphan neuromuscular diseases, who spoke at an investor event hosted by the Muscular Dystrophy Association (MDA).